Item 5. Other Information
Item 5. Other Information.
The information set forth below is included for the purpose of providing disclosure under “Item 1.01 - Entry into a Material Definitive Agreement,” of Form 8-K.
On November 3, 2025, we entered into an Office/Laboratory Lease (the “Emery Lease” or the "Lease") with Emery Station West, LLC (the “Landlord”). The Emery Lease provides for an initial term of thirty-nine (39) calendar months, commencing on October 1, 2026 and expiring on December 31, 2029 (the “Term”), unless earlier terminated pursuant to its terms. In October 2026, the facility will begin serving as our relocated headquarters and primary office, research and laboratory space.
The Lease provides for an initial monthly base rent of approximately $151,232.00 (the “Base Rent”). The Base Rent under the Lease is abated for the first three (3) months of the Term and thereafter increases on a scheduled basis through the end of the Term. In addition to the Base Rent, we will also be responsible for our proportionate share of the building’s operating expenses, including taxes, insurance and maintenance costs, in accordance with the terms of the Lease. In connection with the Lease, we will deliver to the Landlord a letter of credit as a security deposit, subject to reduction as set forth in the Lease.
We also hold certain rights under the Lease, including a continuous right of first refusal to lease any space located on the fourth floor of the building.
The foregoing description of the Emery Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Emery Lease, a copy of which is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.
74
Item 6. Exhibits
Incorporated by Reference
Exhibit
Number
Exhibit Description
Form
Date
Number
Filed
Herewith
3.1
Amended and Restated Certificate of Incorporation.
8-K
5/17/2024
3.1
3.2
Amended and Restated Bylaws of CytomX Therapeutics, Inc., effective March 20, 2024.
8-K
3/22/2024
3.1
4.1
Reference is made to Exhibits 3.1 through 3.2.
4.2
Specimen Common Stock Certificate
S-1/A
9/28/2015
4.1
10.1+
Amendment No. 2 to the Collaboration and License Agreement effective as of October 1, 2025 by and between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc.
X
10.2+
Office/Laboratory Lease, dated November 3, 2025, by and between CytomX Therapeutics, Inc. and Emery Station West, LLC.
X
31.1
Certification of Chief Executive Principal required by Rule 13a-14(a) or Rule 15d-14(a).
X
31.2
Certification of Chief Financial Principal required by Rule 13a-14(a) or Rule 15d-14(a).
X
32.1*
Certification of Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).
X
32.2*
Certification of Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).
X
101.INS
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
X
101.SCH
Inline XBRL Taxonomy Extension Schema Document.
X
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
X
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.
X
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.
X
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
X
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
X
+ Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item (601)(b)(10) of Regulation S-K.
* The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of CytomX Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
75
SIGNA TURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CytomX Therapeutics, Inc.
Date: November 6, 2025
By:
/s/ Sean A. McCarthy
Sean A. McCarthy, D. Phil.
Chief Executive Officer and Chairman
(Principal Executive Officer)
Date: November 6, 2025
By:
/s/ Christopher W. Ogden
Christopher W. Ogden
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
76
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.